Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xtant Medical Holdings (XTNT) EBITDA Margin (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed EBITDA Margin for 16 consecutive years, with 7.64% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin rose 2116.0% to 7.64% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 4.77% through Sep 2025, up 1706.0% year-over-year, with the annual reading at 14.32% for FY2024, 320.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 7.64% at Xtant Medical Holdings, down from 13.06% in the prior quarter.
  • The five-year high for EBITDA Margin was 21.38% in Q4 2022, with the low at 14.13% in Q1 2022.
  • Average EBITDA Margin over 5 years is 5.39%, with a median of 8.78% recorded in 2023.
  • The sharpest move saw EBITDA Margin soared 3507bps in 2022, then plummeted -3492bps in 2023.
  • Over 5 years, EBITDA Margin stood at 13.7% in 2021, then surged by 256bps to 21.38% in 2022, then tumbled by -163bps to 13.54% in 2023, then surged by 56bps to 5.97% in 2024, then skyrocketed by 228bps to 7.64% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 7.64%, 13.06%, and 3.23% for Q3 2025, Q2 2025, and Q1 2025 respectively.